ABNCoV2
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic. On 9 August 2021, it was announced that the first round of trials of the vaccine had been finalized with good results among 45 test subjects.
ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic. On 9 August 2021, it was announced that the first round of trials of the vaccine had been finalized with good results among 45 test subjects.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1247436727 under CC BY-SA 4.0; modifications have been made.